Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "N-Myc down regulation induced differentiation, early cell cycle exit, and apoptosis in human malignant neuroblastoma cells having wild type or mutant p53" [Biochem. Pharmacol. 78 (2009) 1105-1114].

Biochemical pharmacology·2026
Same author

Organoids to Model Tumor Microenvironment in Progression of Pathogenesis and Treatment Resistance in Glioblastoma Multiforme.

Brain sciences·2026
Same author

Emerging advantages of nano delivery systems in enhancing CAR-T/CRISPR-Cas9 mediated cancer therapeutics.

Biochimica et biophysica acta. Reviews on cancer·2026
Same author

Exosome Engineering for Blocking Gut Dysbiosis and Inducing Cell Death Mechanisms in Glioblastoma Multiforme.

Cells·2026
Same author

Acetylated Nanoformulation of N-(4-Hydroxyphenyl)-4-Oxoretinamide Inhibits EZH2-Mediated Epigenetic Repression in Neuroblastoma.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Exosomes as Specific Vehicles for Delivery of Combination Therapies for Inhibiting Autophagy and Inducing Apoptosis in MYCN-Amplified Neuroblastoma Displaying Gut Dysbiosis: Current Challenges and Future Opportunities.

Brain sciences·2026

Related Experiment Video

Updated: May 29, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Targeting angiogenesis for controlling neuroblastoma.

Subhasree Roy Choudhury1, Surajit Karmakar, Naren L Banik

  • 1Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC 29209, USA.

Journal of Oncology
|August 31, 2011
PubMed
Summary

Preventing angiogenesis, the formation of new blood vessels, is a promising strategy for treating malignant neuroblastoma, a challenging childhood cancer. Targeting angiogenesis offers hope for improved patient survival rates.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Related Experiment Videos

Last Updated: May 29, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Area of Science:

  • Pediatric Oncology
  • Cancer Biology
  • Tumor Angiogenesis

Background:

  • Neuroblastoma is a highly vascular, extracranial childhood solid tumor originating from neural crest cells.
  • Malignant neuroblastoma is characterized by angiogenesis, genetic abnormalities, and oncogene amplification, leading to poor patient survivability.
  • Angiogenesis is critical for tumor progression and metastasis in malignant neuroblastoma.

Purpose of the Study:

  • To review the current understanding of angiogenesis in malignant neuroblastoma.
  • To discuss the therapeutic potential of anti-angiogenic agents in treating this disease.
  • To highlight the importance of angiogenesis as a therapeutic target.

Main Methods:

  • Literature review of angiogenesis in malignant neuroblastoma.
  • Analysis of experimental anti-angiogenic agents in preclinical models.
  • Discussion of combination therapy strategies.

Main Results:

  • Angiogenesis plays a pivotal role in the pathogenesis of malignant neuroblastoma.
  • Experimental anti-angiogenic agents show promise in preclinical settings.
  • Targeting angiogenesis is a significant strategy for malignant neuroblastoma treatment.

Conclusions:

  • Preventing angiogenesis is a crucial therapeutic strategy for malignant neuroblastoma.
  • Anti-angiogenic therapies, alone or in combination, represent a promising avenue for future clinical trials.
  • Further research into angiogenesis inhibition is warranted for improved neuroblastoma outcomes.